Skip to Content

Multaq Approval History

  • FDA approved: Yes (First approved July 1st, 2009)
  • Brand name: Multaq
  • Generic name: dronedarone
  • Dosage form: Tablets
  • Company: Sanofi-aventis
  • Treatment for: Atrial Fibrillation, Atrial Flutter

Multaq (dronedarone) is antiarrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter.

Development History and FDA Approval Process for Multaq

Jul  2, 2009Approval FDA Approves Multaq for Patients with Atrial Fibrillation or Atrial Flutter
Mar 19, 2009FDA Advisory Committee Recommends Approval of Multaq (dronedarone)
Aug  8, 2008Multaq (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.